Market Closed -
Nasdaq
04:00:03 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
1.78
USD
|
-2.73%
|
|
-3.26%
|
-17.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
599.6
|
1,157
|
1,173
|
647.6
|
391.4
|
329.1
|
-
|
-
|
Enterprise Value (EV)
1 |
599.6
|
1,157
|
1,173
|
647.6
|
391.4
|
329.1
|
329.1
|
329.1
|
P/E ratio
|
-8.27
x
|
-18.7
x
|
-21.3
x
|
-15.2
x
|
-10.3
x
|
-12.6
x
|
-25.6
x
|
-179
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.03
x
|
12.6
x
|
8.96
x
|
4
x
|
2.5
x
|
1.89
x
|
1.7
x
|
1.51
x
|
EV / Revenue
|
8.03
x
|
12.6
x
|
8.96
x
|
4
x
|
2.5
x
|
1.89
x
|
1.7
x
|
1.51
x
|
EV / EBITDA
|
-9.39
x
|
-20.9
x
|
-25.6
x
|
-52
x
|
-36.5
x
|
105
x
|
24.1
x
|
13.5
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-11,330,058
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
142,089
|
167,142
|
172,266
|
177,421
|
181,197
|
184,890
|
-
|
-
|
Reference price
2 |
4.220
|
6.920
|
6.810
|
3.650
|
2.160
|
1.790
|
1.790
|
1.790
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
74.65
|
91.92
|
130.9
|
162
|
156.4
|
173.8
|
193.5
|
218.5
|
EBITDA
1 |
-63.82
|
-55.22
|
-45.79
|
-12.45
|
-10.72
|
3.12
|
13.66
|
24.3
|
EBIT
1 |
-66.23
|
-58.33
|
-48.94
|
-34.08
|
-30.05
|
-17.9
|
-4.808
|
3.7
|
Operating Margin
|
-88.72%
|
-63.46%
|
-37.4%
|
-21.03%
|
-19.22%
|
-10.3%
|
-2.48%
|
1.69%
|
Earnings before Tax (EBT)
1 |
-70.98
|
-59.57
|
-54.06
|
-42.34
|
-37.32
|
-25.4
|
-12.68
|
-
|
Net income
1 |
-71.24
|
-59.86
|
-54.37
|
-42.78
|
-37.49
|
-25.59
|
-12.82
|
-
|
Net margin
|
-95.44%
|
-65.12%
|
-41.55%
|
-26.4%
|
-23.98%
|
-14.73%
|
-6.63%
|
-
|
EPS
2 |
-0.5100
|
-0.3700
|
-0.3200
|
-0.2400
|
-0.2100
|
-0.1420
|
-0.0700
|
-0.0100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-34.54
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-22.09%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
39.86
|
37.44
|
41
|
39.57
|
44.03
|
30.97
|
38.85
|
39.77
|
46.77
|
38.36
|
42.51
|
44.01
|
48.89
|
41.71
|
46.38
|
EBITDA
1 |
-6.15
|
-3.661
|
-2.414
|
-2.676
|
-3.699
|
-9.754
|
-4.74
|
-0.972
|
4.743
|
-2.709
|
-0.4116
|
1.231
|
5.005
|
-0.683
|
2.643
|
EBIT
1 |
-6.962
|
-9.848
|
-6.835
|
-7.447
|
-9.951
|
-14.15
|
-9.512
|
-5.243
|
0.976
|
-7.979
|
-5.671
|
-3.808
|
-0.444
|
-6.192
|
-2.725
|
Operating Margin
|
-17.46%
|
-26.3%
|
-16.67%
|
-18.82%
|
-22.6%
|
-45.67%
|
-24.48%
|
-13.18%
|
2.09%
|
-20.8%
|
-13.34%
|
-8.65%
|
-0.91%
|
-14.85%
|
-5.88%
|
Earnings before Tax (EBT)
1 |
-9.05
|
-12.21
|
-8.317
|
-8.454
|
-13.36
|
-15.56
|
-13.23
|
-7.208
|
-1.317
|
-9.616
|
-7.653
|
-6.076
|
-2.38
|
-7.771
|
-4.304
|
Net income
1 |
-9.119
|
-12.28
|
-8.389
|
-8.482
|
-13.62
|
-15.62
|
-13.28
|
-7.267
|
-1.328
|
-9.688
|
-7.708
|
-6.092
|
-2.416
|
-7.797
|
-4.33
|
Net margin
|
-22.87%
|
-32.81%
|
-20.46%
|
-21.43%
|
-30.94%
|
-50.43%
|
-34.17%
|
-18.27%
|
-2.84%
|
-25.25%
|
-18.13%
|
-13.84%
|
-4.94%
|
-18.7%
|
-9.34%
|
EPS
2 |
-0.0500
|
-0.0700
|
-0.0600
|
-0.0500
|
-0.0800
|
-0.0900
|
-0.0700
|
-0.0400
|
-0.0100
|
-0.0500
|
-0.0420
|
-0.0320
|
-0.0120
|
-0.0433
|
-0.0233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/22/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/28/23
|
5/4/23
|
8/2/23
|
11/2/23
|
3/5/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-34.5
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
8.94
|
1.62
|
0.91
|
2
|
4.6
|
-
|
-
|
-
|
Capex / Sales
|
11.97%
|
1.76%
|
0.7%
|
1.23%
|
2.94%
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/22/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
1.78
USD Average target price
4.4
USD Spread / Average Target +147.19% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.59% | 338M | | +13.73% | 130B | | -8.17% | 10.97B | | -4.33% | 8.42B | | +41.80% | 5.57B | | -21.94% | 4.59B | | +7.81% | 3.42B | | -10.26% | 2.73B | | -10.29% | 2.08B | | -13.58% | 1.92B |
Medical Devices & Implants
|